My research group uses unique proteomics and computational approaches to understand how cell signalling pathways driven by the activity of protein kinases contribute to the development of cancer. Increasing this knowledge will be invaluable in advancing personalised cancer therapies.
My lab utilises state-of-art multi-omics methodologies to study how protein synthesis is dysregulated in cancer cells, and how this dysregulation contributes to various stages of cancer progression.
The overarching goal of our laboratory is to understand the biology of normal haematopoietic and leukaemic stem cells in order to selectively kill cancer stem cells for better leukaemia treatment.
My research focuses on kinase biology and how kinase signalling pathways are hijacked in cancer. We combine computational biology with proteomics and cell biology to uncover novel ways to target these dysregulated networks.
My group studies how RNA-mediated mechanisms, in particular long noncoding RNAs, regulate cell division and how dysregulation of these processes leads to genome instability and cancer.
My research focuses on understanding the role of RNA localisation in breast cancer progression. In particular, I am looking at how and why the cellular localization of some small nuclear RNAs (snoRNA) are altered during disease progression.
My focus is on investigating the epigenetic regulation of the PI3K pathway and identifying an effective combination therapy that will disable compensatory bypass routes, overcoming drug resistance.
My project focuses on the translation reprogramming in acute myeloid leukaemia upon stresses such as chemotherapy.
My research focuses on exploiting cell cycle vulnerabilities and signalling rewiring in tumour cells, to find new approaches to treat cancer.